SCHEMBL1591801

SCHEMBL1591801

Cc1cc(Oc2ccc(NS(=O)(=O)c3ccc(-c4cnco4)s3)cc2)c2cc(F)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GHSR Q92847 2/20 0.46
▸ MAPT P10636 7/20 0.45
▸ PFKFB3 Q16875 1/20 0.42
▸ TP53 P04637 5/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ POLB P06746 2/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ PSEN1 P49768 1/20 0.34
▸ PSEN2 P49810 1/20 0.34
▸ APH1B Q8WW43 1/20 0.34
▸ NCSTN Q92542 1/20 0.34
▸ APH1A Q96BI3 1/20 0.34
▸ PSENEN Q9NZ42 1/20 0.34
▸ PGR P06401 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1591669 0.82 SMN1; SMN2 (0.47) MAPTKMT2AMEN1LMNANPC1
SCHEMBL1591137 0.76 PGR (0.50) MAPTKMT2AMEN1LMNANPC1
SCHEMBL1591224 0.76 FFAR1 (0.56) MAPTPGR
SCHEMBL1592203 0.75 AXL (0.47) TP53KMT2AMEN1LMNA
SCHEMBL1592197 0.75 RORC (0.51) KMT2AMEN1LMNACYP3A4CYP2D6
SCHEMBL1591277 0.73 ATM (0.44) MAPTKMT2AMEN1LMNANPC1
SCHEMBL1592072 0.73 PGR (0.55) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL1591088 0.72 PGR (0.60) MAPTPFKFB3KMT2AMEN1LMNA
SCHEMBL1590907 0.71 PGR (0.58) PGR
SCHEMBL1591259 0.71 ATM (0.55) KMT2AMEN1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US claimed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 — — US disclosed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 — — US disclosed
EP-2262772-B1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2012-07-18 — — EP disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed
WO-2009127417-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS AXL, FLT3, TYRO3 GHSR 850/4885MAPT 3163/4885PFKFB3 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback